Skip to content
Labcoat
  • Investors
  • Insights
  • Login

JOIN THE COMMUNITY

Labcoat
  • Investors
  • Insights
  • Login

Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations

Biotech Hub / By Sal Daher, CFA

Click the image to the left and log in to get your exclusive reader perks.
https://www.thedailytimes.com/business/tevogen-bio-announces-its-investigational-sars-cov-2-specific-t-cell-therapy-tvgn-489-is/article_3f50db92-2e9c-563a-951e-b1cbe1f6b291.html

Post navigation
← Previous Post
Next Post →

Related Posts

Investors see promise in digital health — the challenge is adoption

Biotech Hub

Health care workers say this is not the time to wait for a flu shot

Biotech Hub / By Sal Daher, CFA

Subscribe to Newsletter

Labcoat Ventures

We work with angel investors to fund the most promising early-stage biotechs.

Copyright © 2025

  • Investors
  • Insights
  • Biotech Hub